alexa Abstract | Does Adriamycine, Cytoxan with Taxol Treatment Affect FBS and Lipid Profile in Breast Cancer Patients

Archives of Medicine
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article Open Access


Introduction: Many breast cancer survivors experience post-treatment metabolic complications based on their regimen. Various results have been reported regarding tamoxifen therapy effects on lipid profile and FBS level. But, no study investigate adriamycine, cytoxan with taxol treatment on them one year after finishing the treatment.
Patients and method: Breast cancer patients under adriamycine, cytoxan with taxol regimen were chosen. FBS and lipid profile items were measured before the treatment and one year after the treatment ended. Patients have been monitored during the year after therapy. These two pairs were compared and Sig<0.05 showed meaningful relation.
Result: A total of 114 breast cancer patients with stage III or IV were participated in this cross-sectional study. Our analysis showed this regimen had no significant impact on FBS and lipid profile items one year after finishing the treatment.
Conclusion: In summery the findings of the current study showed adriamycine, cytoxan with taxol regimen had no meaningful impact of FBS and lipid profile level one year after the treatment. It is advised to monitor breast cancer metabolic items during and after the treatment.

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): Simin Hemati Mansour Siavash Dastjerdi Minu Jelvan


Adriamycine, Cytoxan, Taxol, Breast cancer, Lipid profile, FBS, General Medicine

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version